Galectin Therapeutics (GALT) Total Liabilities (2010 - 2026)

Galectin Therapeutics has reported Total Liabilities for 17 years, with the latest figure at $146.0 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 19.88% year-over-year to $146.0 million; the trailing twelve-month figure through Mar 2026 stood at $146.0 million (up 19.88% YoY), and the FY2025 full-year result was $145.7 million, up 20.87% from the prior year.
• Total Liabilities for Q1 2026 stood at $146.0 million, roughly flat from $145.7 million in the prior quarter.
• The five-year high for Total Liabilities was $146.0 million in Q1 2026, with the low at $39.8 million in Q1 2022.
• Average Total Liabilities over 5 years is $94.2 million, with a median of $97.0 million recorded in 2024.
• Year-over-year, Total Liabilities jumped 753.7% in 2022 and gained 12.34% in 2025.
• Tracing GALT's Total Liabilities over 5 years: stood at $53.5 million in 2022, then soared by 65.38% to $88.4 million in 2023, then surged by 36.32% to $120.6 million in 2024, then rose by 20.87% to $145.7 million in 2025, then advanced by 0.18% to $146.0 million in 2026.
• The last three Total Liabilities figures came in at $146.0 million (Q1 2026), $145.7 million (Q4 2025), and $136.4 million (Q3 2025), per Business Quant data.

Peer Comparison